ArticleHereditas2026
Clinical value of miR-551b-5p in children with primary nephrotic syndrome and its regulatory role in disease progression.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary nephrotic syndrome (PNS) is a common glomerular disorder in children. Despite significant advances in glucocorticoid therapy, considerable challenges remain in the early diagnosis and prognostic management of PNS. Elevated miR-551b-5p expression has been detected in the PNS. This study aims to further explore the role of miR-551b-5p in the onset and progression of PNS and its potential mechanisms.
methodsA total of 107 patients with primary nephrotic syndrome (PNS) and 99 healthy volunteers (HV) were included in this study. And the PNS group was further divided into subgroups with favorable (n = 76) and poor (n = 31) prognosis. The expression of miR-551b-5p in the PNS and the poor prognosis group was quantified using qRT-PCR. The predictive capability of miR-551b-5p for the occurrence and poor prognosis of PNS was evaluated. The effects of miR-551b-5p knockdown on podocyte growth and inflammatory injury were examined. The interaction between miR-551b-5p and CD2AP was verified via database and luciferase assay.
resultsmiR-551b-5p is obviously elevated in PNS and the poor prognosis group. miR-551b-5p exhibits strong diagnostic capability for both the onset and poor prognosis of pediatric PNS. High miR-551b-5p expression is an independent risk factor for poor prognosis in pediatric PNS patients. miR-551b-5p downregulation potently promotes podocyte proliferation and reduces apoptosis, and improves intracellular inflammatory responses and oxidative stress levels. Furthermore, CD2AP is a direct target of miR-551b-5p, and this regulatory axis synergistically contributes to the pathogenesis and progression of PNS.
conclusionmiR-551b-5p is a potential biomarker for predicting the occurrence and poor prognosis of PNS. miR-551b-5p promotes the onset and progression of PNS by targeting CD2AP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.